UK pharma major GlaxoSmithKline (LSE: GSK) has received clearance from the European Commission for its proposed three-part transaction with Swiss drug major Novartis (NOVN: VX).
The deal, announced in April last year, includes the acquisition of Novartis’s vaccines business (excluding influenza vaccines), the creation of a consumer health care joint venture between GSK and Novartis and the divestment to Novartis of GSK’s marketed oncology portfolio, related R&D activities and rights to two pipeline AKT inhibitors.
The European Commission’s approval is subject to certain conditions, which GSK and Novartis have agreed to undertake following completion of the proposed transaction. GSK also agreed to sell its meningitis vaccines, Nimenrix and Mencevax, on a global basis. These vaccines are marketed outside of the USA and generated annual global sales of £36 million ($54.5 million) in 2013. GSK will also divest two small Novartis bivalent vaccines for protection against diphtheria and tetanus in Italy and Germany.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze